Related Experiment Video
Updated: Jun 12, 2025

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Disulfidptosis: A New Target for Parkinson's Disease and Cancer
Tingting Liu1, Xiangrui Kong1, Jianshe Wei1
1Institute for Brain Sciences Research, School of Life Sciences, Henan University, Kaifeng 475004, China.
Abstract:
Recent studies have uncovered intriguing connections between Parkinson's disease (PD) and cancer, two seemingly distinct disease categories. Disulfidptosis has garnered attention as a novel form of regulated cell death that is implicated in various pathological conditions, including neurodegenerative disorders and cancer. Disulfidptosis involves the dysregulation of intracellular redox homeostasis, leading to the accumulation of disulfide bonds and subsequent cell demise. This has sparked our interest in exploring common molecular mechanisms and genetic factors that may be involved in the relationship between neurodegenerative diseases and tumorigenesis. The Gene4PD database was used to retrieve PD differentially expressed genes (DEGs), the biological functions of differential expression disulfidptosis-related genes (DEDRGs) were analyzed, the ROCs of DEDRGs were analyzed using the GEO database, and the expression of DEDRGs was verified by an MPTP-induced PD mouse model in vivo. Then, the DEDRGs in more than 9000 samples of more than 30 cancers were comprehensively and systematically characterized by using multi-omics analysis data. In PD, we obtained a total of four DEDRGs, including ACTB, ACTN4, INF2, and MYL6. The enriched biological functions include the regulation of the NF-κB signaling pathway, mitochondrial function, apoptosis, and tumor necrosis factor, and these genes are rich in different brain regions. In the MPTP-induced PD mouse model, the expression of ACTB was decreased, while the expression of ACTN4, INF2, and MYL6 was increased. In pan-cancer, the high expression of ACTB, ACTN4, and MYL6 in GBMLGG, LGG, MESO, and LAML had a poor prognosis, and the high expression of INF2 in LIHC, LUAD, UVM, HNSC, GBM, LAML, and KIPAN had a poor prognosis. Our study showed that these genes were more highly infiltrated in Macrophages, NK cells, Neutrophils, Eosinophils, CD8 T cells, T cells, T helper cells, B cells, dendritic cells, and mast cells in pan-cancer patients. Most substitution mutations were G-to-A transitions and C-to-T transitions. We also found that miR-4298, miR-296-3p, miR-150-3p, miR-493-5p, and miR-6742-5p play important roles in cancer and PD. Cyclophosphamide and ethinyl estradiol may be potential drugs affected by DEDRGs for future research. This study found that ACTB, ACTN4, INF2, and MYL6 are closely related to PD and pan-cancer and can be used as candidate genes for the diagnosis, prognosis, and therapeutic biomarkers of neurodegenerative diseases and cancers.
Insights
Parkinson's disease (PD) and cancer share common molecular links. Four genes (ACTB, ACTN4, INF2, MYL6) involved in disulfidptosis are identified as potential biomarkers for both conditions.
Area of Science:
- Biomedical Science
- Oncology
- Neuroscience
Background:
- Parkinson's disease (PD) and cancer are distinct conditions with emerging molecular connections.
- Disulfidptosis, a novel regulated cell death pathway, is implicated in both neurodegeneration and tumorigenesis.
- Understanding shared mechanisms is crucial for identifying novel therapeutic targets.
Purpose of the Study:
- To explore common molecular mechanisms and genetic factors linking Parkinson's disease and cancer.
- To identify differentially expressed disulfidptosis-related genes (DEDRGs) in PD and pan-cancer.
- To evaluate the diagnostic and prognostic potential of identified DEDRGs.
Main Methods:
- Utilized the Gene4PD database to identify PD differentially expressed genes (DEGs).
- Analyzed biological functions and ROCs of DEDRGs using GEO database and an MPTP-induced PD mouse model.
- Performed multi-omics analysis on over 9000 cancer samples to characterize DEDRGs.
Main Results:
- Identified four key DEDRGs in PD: ACTB, ACTN4, INF2, and MYL6, enriched in pathways like NF-κB signaling and apoptosis.
- Observed altered expression of these genes in PD models and correlated high expression with poor prognosis in various cancers.
- Found significant immune cell infiltration and identified potential microRNAs (e.g., miR-4298) and drugs (e.g., cyclophosphamide) associated with DEDRGs.
Conclusions:
- ACTB, ACTN4, INF2, and MYL6 are strongly associated with both Parkinson's disease and pan-cancer.
- These genes serve as promising candidate biomarkers for diagnosis, prognosis, and therapy in neurodegenerative diseases and cancers.
- Disulfidptosis represents a potential unifying mechanism linking PD and cancer pathogenesis.
More Related Videos
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
04:01Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Targeted Cancer Therapies
There are several types of targeted therapies against...
Neural Regulation
Drugs that Stabilize Microtubules
mTOR Signaling and Cancer Progression
The mTOR pathway or the...